Long-Lasting Response of Bone Metastases from RA223-Treated Breast Cancer: A Case Report

Abstract

Renato Patrizio Costa, Vincenzo Tripoli, Alessandro Princiotta, Alessandra Murabito, Maria Licari, Francesco Verderame, Alfredo Colombo, Vittorio Gebbia and Antonio Pinto

Radium 223 dichloride (Ra223) is a novel first in class alpha emitting radiopharmaceutical that has been approved for the treatment of castration resistance prostate cancer with bone metastases. Radium 223 was demonstrated to improve overall survival and symptoms in patients with CRPC in ALSYMPCA trial. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223, after obtaining informed consent. Were administered six treatments of Ra223. The patient did not develop skeletal related events (SREs; i.e., radiation to bone, pathological fracture, spinal cord compression, surgery to bone), the major complications of bone metastases, up to now. Radium 223 has improved patient survival and it has eliminated bone pain whilst keeping hematological toxicity to a minimum. It is, to our knowledge, the first example of complete recovery of bone metastatic disease treated with Ra223, published to data. We have shown that Radium223 dichloride can be safely administered in hormone refractory bone metastases from breast cancer; Radium 223 may play a critical role in the management of breast cancer.

PDF